Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking HypopigmentationBrian T. O’Neill, Michael A. Brodney, Gabriela Barreiro et al.|Journal of Medicinal Chemistry|2018Cited by 42
P1–386: Cross‐species analysis of cerebrospinal fluid (CSF) beta‐amyloid reductions by the BACE1 inhibitor PF‐05297909 indicates species differences in PK/PD relationships: Relevance to clinical translationÉva Hajós‐Korcsok, David Riddell, Charles E. Nolan et al.|Alzheimer s & Dementia|2013Cited by 0
P4–291: Predicting <i>in vivo</i> BACE inhibitor efficacy: Are human iPS‐derived neurons superior?Christine Oborski, David Riddell, Sandra J. Engle et al.|Alzheimer s & Dementia|2013Cited by 0
P2–379: Disconnect between brain and CSF drug exposure and beta‐amyloid levels following BACE inhibitionCathleen Gonzales, David Riddell, Claude Ambroise et al.|Alzheimer s & Dementia|2013Cited by 0
CCDC 1829109: Experimental Crystal Structure DeterminationBrian T. O’Neill, Michael A. Brodney, Elizabeth M. Beck et al.|The Cambridge Structural Database|2018Cited by 0